CEO Executive AssistantThe respiratory pharmaceutical market is one of the most competitive and technically complex in the industry. Managing a respiratory portfolio demands that a pharma CEO balance cutting-edge inhaler device technology, demanding payer negotiations, specialty physician engagement, and a regulatory landscape that scrutinizes both efficacy and safety with extraordinary rigor. This guide covers the core business operations that define excellence in respiratory portfolio management.
Understanding the Respiratory Market Landscape
Respiratory disease affects hundreds of millions of people globally. Chronic Obstructive Pulmonary Disease (COPD) and asthma together represent the largest patient populations in the respiratory space, but the market also encompasses pulmonary arterial hypertension, idiopathic pulmonary fibrosis, and a growing category of biologics for severe asthma with specific inflammatory phenotypes.
The competitive dynamics are fierce. The inhaled corticosteroid and long-acting beta-agonist combination market has faced significant generic pressure. Newer biologic therapies targeting IL-4, IL-5, and IL-13 pathways have redefined the standard of care for severe eosinophilic asthma and introduced new commercial complexity around biomarker-driven prescribing and specialty pharmacy distribution.
A pharma CEO managing a respiratory portfolio must understand not just the clinical science but the market access implications of each mechanism of action, the device landscape, and the evolving diagnostic standards that determine which patients receive which therapies.
COPD and Asthma Program Operations
Managing COPD and asthma programs requires distinct operational strategies despite the fact that both fall under the respiratory umbrella. The patient populations, prescriber bases, payer dynamics, and adherence challenges differ significantly.
COPD program operations focus heavily on primary care and pulmonology engagement. Most COPD patients are diagnosed and managed in primary care settings, making general practitioner outreach a core commercial activity. However, pulmonologists drive prescribing of advanced therapies, particularly in the moderate-to-severe COPD population where triple therapy combinations are now standard.
Market access for COPD products is complex because the patient population skews older, with significant Medicare and Medicaid coverage. Prior authorization requirements, step therapy protocols, and formulary tier placement all directly affect patient access and market share. CEOs must ensure that the market access team is resourced to work through these barriers proactively with payer medical directors.
Asthma program operations have been transformed by the biologics revolution. Severe asthma biologics such as dupilumab, mepolizumab, and benralizumab require biomarker testing before prescribing, specialty pharmacy distribution, and patient support programs that are more complex than traditional retail pharmacy channels. CEOs managing biologic asthma programs must invest heavily in specialty pharmacy relationships, HUB services, and patient navigator support.
Mild-to-moderate asthma, by contrast, is largely managed through primary care and urgent care settings. Programs targeting this population require efficient sampling, digital engagement, and formulary management with commercial payers.
Inhaler Technology: A Strategic Differentiator
In the respiratory pharmaceutical market, the device is often as important as the molecule. Inhaler technology directly affects drug delivery, patient adherence, and clinical outcomes. For a pharma CEO, device strategy is a core business operations priority.
Device portfolio management encompasses multiple inhaler categories: pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), soft mist inhalers, and nebulizers. Each has different patient suitability profiles, training requirements, and cost structures. A CEO must understand where each device fits in the therapeutic area and ensure that device selection is guided by patient preference data, not just manufacturing convenience.
Digital inhaler technology represents a significant and growing opportunity. Connected inhalers with sensors that track usage, detect errors, and feed data to patient-facing apps and provider dashboards are moving from pilot programs to commercial deployment. CEOs who invest early in digital inhaler integration position their respiratory portfolio for outcomes-based contracting and real-world evidence generation.
Device training and patient support programs are essential for maximizing clinical outcomes and minimizing return rates. Studies consistently show that a significant percentage of patients use inhalers incorrectly, reducing drug delivery and clinical benefit. A well-designed patient onboarding program with pharmacist counseling, instructional video access, and follow-up touchpoints can materially improve outcomes data and support payer negotiations.
Sustainability considerations for inhaler devices are becoming increasingly important. pMDIs use hydrofluorocarbon propellants with significant global warming potential. Regulatory and market pressures in Europe and increasingly in the United States are pushing the industry toward lower-emission alternatives. CEOs should have a device sustainability roadmap that anticipates regulatory requirements and responds to payer and health system sustainability commitments.
Payer Coverage Strategy: Winning Formulary Position
Formulary placement is the single most powerful determinant of market access for respiratory products. A product on Tier 2 of a preferred formulary will dramatically outperform the same product on Tier 3 or with prior authorization requirements, all else being equal.
Payer segmentation should drive coverage strategy. Commercial payers, Medicare Part D plans, Medicaid managed care organizations, and integrated delivery network (IDN) formularies each have different decision-making processes, stakeholders, and value drivers. A CEO must ensure that the market access team has a distinct strategy for each payer segment, not a one-size-fits-all approach.
Value dossiers and HEOR evidence are the currency of payer negotiations. Health economics and outcomes research (HEOR) evidence demonstrating cost-effectiveness, reduction in exacerbations, hospitalizations, and emergency department visits is essential for securing preferred formulary placement. CEOs should ensure that the HEOR strategy is aligned with commercial launch planning and that data is available in the formats that payer medical and pharmacy directors actually use.
Outcomes-based contracts with payers are an emerging strategy in the respiratory space, particularly for high-cost biologics. These agreements tie rebates or price adjustments to real-world performance metrics such as exacerbation rates or adherence levels. Executing outcomes-based contracts requires sophisticated data infrastructure, clear contract language, and a willingness to stand behind product performance claims.
Patient assistance and affordability programs address cost-related access barriers for uninsured and underinsured patients. For respiratory biologics, where list prices can exceed $30,000 annually, robust patient assistance programs are a commercial and ethical necessity. CEOs should track program utilization, patient outcomes, and administrative costs to ensure these programs are both effective and financially sustainable.
For frameworks on navigating pharma pricing and coverage, see pricing and market access ops.
Pulmonologist Engagement: The Specialist Strategy
Pulmonologists are the key influencers in the respiratory pharmaceutical market, particularly for severe asthma biologics, COPD triple therapy, and pulmonary hypertension. Building effective relationships with this specialist community requires a sophisticated engagement strategy that goes beyond traditional sales calls.
Thought leader development starts with identifying and engaging the pulmonologists and allergist-immunologists who shape prescribing patterns at academic medical centers, major community health systems, and professional societies. These key opinion leaders (KOLs) should be engaged early in clinical development through advisory boards, speaker programs, investigator-initiated trials, and publication support.
Medical science liaison (MSL) programs provide the non-promotional scientific engagement that specialist physicians increasingly expect. MSLs engage with pulmonologists on clinical data interpretation, real-world evidence, disease state education, and research collaboration. CEOs should ensure that MSLs are deeply trained in respiratory science and empowered to have substantive peer-to-peer scientific conversations.
Congress and society presence at the American Thoracic Society (ATS), European Respiratory Society (ERS), and American College of Allergy, Asthma, and Immunology (ACAAI) is essential for respiratory portfolio visibility. Major clinical data presentations at these congresses drive prescriber awareness and shape standard-of-care perceptions. CEOs should ensure that the medical affairs and commercial teams coordinate congress strategy tightly.
Digital engagement channels have become increasingly important for reaching pulmonologists in the wake of reduced in-person access. Virtual advisory boards, webinars, digital content platforms, and sponsored medical education are all part of the modern specialist engagement toolkit.
Regulatory Operations for Respiratory Products
Respiratory products face a rigorous regulatory pathway with specific requirements around device characterization, clinical endpoint selection, and post-marketing surveillance.
New drug application (NDA) and supplemental NDA management for respiratory products requires specialized regulatory expertise in device-drug combination products, aerosol characterization, and the respiratory endpoint standards established by FDA guidance. CEOs should ensure that regulatory affairs leadership has deep respiratory experience, not just general pharma regulatory expertise.
Post-marketing commitments for respiratory products frequently include long-term safety studies, pediatric studies, and REMS programs for products with specific risk profiles. Managing these commitments on time and within budget is essential for maintaining regulatory standing and avoiding enforcement actions.
Label optimization through supplemental applications can expand indications, add patient subgroups, or update safety information in ways that have significant commercial implications. CEOs should treat label management as an ongoing business activity, not a one-time launch task.
For a comprehensive view of pharma regulatory operations, see regulatory compliance ops.
Pipeline Management and Portfolio Strategy
A respiratory portfolio without a pipeline is a business in decline. CEOs must simultaneously manage in-line commercial products and advance a pipeline that addresses unmet needs and positions the organization for future growth.
Pipeline prioritization in respiratory should be grounded in unmet need, competitive landscape analysis, and platform fit. Mechanisms targeting novel inflammatory pathways, such as TSLP, IL-33, or the epithelial cytokine cascade, are attracting significant investment. Small molecule approaches to mucus clearance, airway remodeling, and inflammation also offer differentiation opportunities.
Business development and licensing play an important role in respiratory portfolio building for mid-size and large pharma companies. CEOs should maintain active business development relationships with biotech companies, academic medical centers, and platform technology developers to identify in-licensing, co-development, or acquisition opportunities that strengthen the portfolio.
Lifecycle management of in-line products through new formulations, device upgrades, new indications, and combination products extends commercial value and protects revenue during patent cliff transitions. A disciplined lifecycle management program should be part of every respiratory product’s commercial strategy from launch.
Commercial Excellence and Field Force Operations
The respiratory field force, including sales representatives, key account managers, and MSLs, is the primary commercial execution engine. Field force effectiveness has an outsized impact on respiratory portfolio performance given the relatively concentrated prescriber base in pulmonology and allergy.
Field force sizing and deployment should be driven by prescriber targeting analytics. In respiratory, the top decile of prescribers often accounts for the majority of total prescriptions. Ensuring that field time and resource allocation are weighted toward high-value prescribers is a fundamental commercial discipline.
Sales force training in respiratory must cover not just product knowledge but device training, disease state education, and payer and reimbursement navigation. Representatives who can help office staff navigate prior authorization processes create significant value for prescribers and build lasting relationships.
Performance management systems for the respiratory field force should track leading indicators, such as call frequency, sample distribution, and key account access, as well as lagging indicators such as market share and prescription volume. CEOs who rely only on trailing prescription data are flying blind for most of the commercial cycle.
According to McKinsey, respiratory commercial excellence is increasingly driven by digital engagement integration alongside traditional field force activity, with companies that combine both channels outperforming single-channel peers on market share growth.
Financial Management of the Respiratory Portfolio
Respiratory portfolio financial management requires discipline across revenue forecasting, gross-to-net management, investment allocation, and cost control.
Gross-to-net management is particularly complex in respiratory because of the substantial rebates paid to pharmacy benefit managers and health plan formulary gatekeepers. Net price realization for a branded respiratory product can be 50 percent or less of list price. CEOs must ensure that contract and pricing teams model gross-to-net scenarios rigorously before entering payer agreements.
Revenue forecasting for respiratory products must account for payer dynamics, competitive launches, generic entries, and the staggered impact of formulary wins and losses throughout the year. Scenario planning that models optimistic, base, and pessimistic cases gives leadership the range needed to make sound investment decisions.
Portfolio investment allocation between commercial support, pipeline advancement, HEOR, and infrastructure should reflect the stage and competitive position of each asset. An in-line product defending market share against generics requires different investment than a late-stage pipeline asset approaching launch.
Mastering respiratory portfolio business operations requires a CEO who is simultaneously a scientist, a commercial strategist, a payer negotiator, and a talent developer. The complexity is formidable, but respiratory portfolios that are managed with operational rigor consistently deliver strong returns and meaningful patient impact.
Related Reading
For further context, explore Pharma CEO Business Operations Checklist and Allergy Portfolio Pharma CEO Business Operations: Strategic Execution Guide.